Dublin, Nov. 01, 2018 (GLOBE NEWSWIRE) -- The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering.
This report organizes information from diverse sources into sections, including an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements and patents.
The scope of this report includes an overview of the global market scenario for diagnosis and treatments of HIV, with base year data from 2017, estimations for 2018 and forecasts for 2023 using projections of CAGR during the forecast period. Market data in terms of value is provided at global, regional and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
The report forecasts the global market for HIV therapeutics by drug class and discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase stand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.
Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.
Market dynamics, such as trends and challenges, are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. The regional overviews provide information on the epidemiology of HIV by country and region and details market data for each region. The regulatory scenario is discussed for the United States, Europe and Japan to provide an overview of the regulations for new drug launches and diagnostic kits.
The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to readers of this report. The pipeline analysis chapter discusses four major drug categories to provide details on major pipeline developments. The competitive landscape discusses the major manufacturers involved in the HIV therapeutics market, key developments and product offerings.
The Report Includes:
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Characterization and quantification of market potential for therapeutic drugs for HIV virus by drug categories, diagnostic test types, application sectors and geographical regions
- Country-specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
- Evaluation of the market dynamics such as drivers, restraints and current industry trends and patterns
- Discussion of the regulatory scenario for United States, Europe, and Japan to provide an overview of the regulations for new drug launches and diagnostic kits
- Examination of cost implications for treatments across a range of countries
- A look at ongoing research and the future direction of the market
- Assessment of the competitive landscape and discussion of the major manufacturers involved in the HIV therapeutics market, key developments and product offerings, including Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., GlaxoSmithKline, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific
Key Topics Covered:
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
- Overview of Human Immunodeficiency Virus (HIV)
- Report Overview
- Disease Prognosis
- Symptoms
- Treatments
- HIV Timeline and Milestones
- HIV Life Cycle: Treatment and Mechanism of Action
- HIV Prophylaxis
- Pre-exposure Prophylaxis (PrEP)
- Post-exposure Prophylaxis (PEP)
- Drug Resistance
- Medication Adherence
- WHO Initiatives
Chapter 4 Global Industry Trends
- Trends in Global HIV Transmission
- Regional Awareness Programs
- Development of Novel Therapies
- Public-Private Partnerships
- Rising Comorbidities in HIV Patients with an Increase in the Longevity of Patients
- Global Programs to Counter HIV
- Preventing Transmission from Mother to Child
- Challenges
- Underestimating the Risk of Contracting the Disease
- Social Stigma Associated with STDs
- High Cost of Treatment
Chapter 5 Global HIV Therapeutics Market
- Global HIV Therapeutics Market and Forecast Overview
- North American HIV Therapeutics Market
- Epidemiology
- HIV Testing and Recommendations
- Regulations Impacting the North American HIV Therapeutics Market
- Market Analysis and Forecast
- European HIV Therapeutics Market
- Epidemiology
- HIV Testing and Recommendations
- Regulations Impacting the European HIV Market
- Market Analysis and Forecast
- Asia-Pacific HIV Therapeutics Market
- Epidemiology
- Prevention and Screening Programs
- Regulations Impacting the Asia-Pacific HIV Market
- Market Impact of Generic Manufacturers
- Market Analysis and Forecast
- Rest of World (RoW) HIV Therapeutics Market
- Epidemiology
- Market Analysis and Forecast
- Global Investments in HIV Market
Chapter 6 HIV Therapeutics Market by ARV Drug Categories
- Timeline of Therapies
- First-Line Treatment Regimen
- Second-line Treatment Regimen
- Third-line/Salvage Treatment Regimen
- Market Overview by Drug Category
- Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
- Protease Inhibitors (PIs)
- Single-Tablet Regimen (STR)/Fixed-Dose Combination (FDC) Drugs
- Integrase Strand Transfer Inhibitors (INSTI)
- Non-nucleotide Reverse Transcriptase Inhibitors (NNRTIs)
- Entry Inhibitors
Chapter 7 Leading Drugs in the HIV Therapeutics Market
- Leading HIV Drugs
- Drug Profiles
- Genvoya
- Triumeq
- Truvada
- Tivicay (Dolutegravir)
- Prezista/Prezcobix/Rezolsta/Symtuza
- Atripla
- Descovy
- Isentress/Isentress HD
- Odefsey
- Stribild
- Eviplera
- Viread
- Promising Emerging Therapies
- Darunavir/Cobicistat/FTC/TAF Fixed-dose Combination
- Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
- Ibalizumab (Trogarzo)
- Estimated Drug Revenue Forecast
- Genvoya
- Triumeq and Tivicay
- Odefsey
- Stribild
Chapter 8 HIV Diagnostics Market
- HIV Diagnostics Market by Test Type
- Evolution of HIV Tests
- Antigen- and Antibody-Based Tests
- Future Perspective
- CD4 Testing
- Future Perspective
- Viral Load Testing
- Future Perspective
- HIV Diagnostics Product Profiles by Test Type
- CD4 Testing Products
- Viral Load Testing Products
Chapter 9 Pipeline Analysis
- HIV Pipeline Overview
- Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Drugs in Development
- NNRTI Drugs in Development
- Doravirine/TDF/3TC
- Other Categories
- Generic Dolutegravir (Integrase Inhibitors)
- Albuvirtide (Aikening) (Fusion inhibitors)
- Juluca (Dolutegravir/Rilpivirine)
- Isentress HD (Raltegravir) (Integrase Inhibitors)
- Combination Therapies
- Approved and Tentatively Approved Antiretrovirals
Chapter 10 Regulatory and Reimbursement Structure
- Overview of Regulations
- United States
- Europe
- Japan
- China
- Overview of Pricing and Reimbursement
- United States
- Europe
- Japan
Chapter 11 Competitive Landscape and Key Developments
- Market Share Analysis
- Patent Analysis
- Key Developments
Chapter 12 Company Profiles
- Abbott Laboratories
- Abbvie Inc.
- Agilent Technologies Inc.
- Aurobindo Pharma Ltd.
- Becton, Dickinson And Co.
- Bio-Rad Laboratories Inc.
- Bristol-Myers Squibb Co.
- Cepheid Inc.
- Gilead Sciences Inc.
- Glaxosmithkline Plc
- Hoffmann-La Roche Inc.
- Hologic Inc.
- Janssen Pharmaceuticals Inc.
- Merck & Co. Inc.
- Meridian Life Science Inc.
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
- Viiv Healthcare
For more information about this report visit https://www.researchandmarkets.com/research/5jxpc9/global_hiv?w=12
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: HIV/AIDS Drugs